Asset Management

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, announced June 15 that the European Commission has approved its planned acquisition of U.S.-based life science company Sigma-Aldrich.

It has been over 40 months since President Obama signed the Leahy-Smith America Invents Act (AIA) into law in September 2011, climaxing years of feverish legislative wrangling. AIA was heralded as a game-changer, the dawning of an equitable intellectual property (IP) regimen that rewarded research scientists and innovators beset by ineffectual patent processes and procedures.

New methods are improving connections between private businesses and technology from the Department of Energy’s Oak Ridge National Laboratory, with 101 licenses and options executed during the last three years.

SP Industries, Inc. (SP), a leading designer and manufacturer of state-of-the-art laboratory equipment, biological drug manufacturing solutions, and specialty glassware, has announced that it has acquired privately held Bel-Art Products (Bel-Art). Headquartered in Wayne (NJ, USA), Bel-Art is a global provider of innovative laboratory solutions serving the scientific, industrial, and healthcare end markets.

Much has been written about the business benefits of outsourcing “noncore” activities, and this approach is now well-established in most chemical, pharmaceutical, and biotech companies. By concentrating on core areas and working with specialists for other tasks, costs are better managed, efficiency is boosted, and ROI (return on investment) is increased.

Thanks to cuts to research funding, the DIY movement continues to be a growing trend in laboratories across the U.S., according to a recent article in the Star Tribune.

A bill to be heard today (Feb. 10) before the Wisconsin state Assembly's education committee would keep scientific research from the public eye if it passes.

According to a recent article by Jeff John Roberts of Gigaom, a 1997 patent held by Boston University (BU) could actually be detrimental to public research.











